Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments Inc announce clinical results of a clinical trial investigating Highland Instruments’ novel noninvasive neuromodulation technology electrosonic stimulation to treat chronic osteoarthritis knee pain (ALGEA 2).
The double-blinded randomized controlled trial studied 64 patients that underwent a course of Highland’s ESStim therapy, given 20 minutes/day over 10 days and were assessed up to 8 weeks post therapy. Study end-points were successfully achieved, with clinically and statistically significant improvements in patient pain reduction, reduced drug use, and improved biomechanics.
At 1 month post ESStim therapy, patient Visual Analogue Scale (VAS) pain scores were reduced by ~53% (Active) vs ~22% (SHAM) (p<0.05). Additionally, Active ESStim therapy patients consumed approximately 1/3 of pain medications vs. SHAM patients through the trial (assessed as Acetaminophen Equivalent use per day).
“We have seen great results with ESStim across the chronic pain and movement disorder indications. While the data speaks for itself, such as the sustained reduced pain in the chronic pain patients and improved mobility in the Parkinson’s patients, a noninvasive approach which can improve patient’s quality of life without the side-effects of drugs is very exciting.”— Spaulding Principal Investigator, Felipe Fregni, MD, PhD, MMSc, MPH, MEd
[Source(s): Highland Instruments Inc, PR Newswire]